In vitro studies demonstrate improved outcomes in bone remodeling and MRSA infection using DNA nanocarriers, suggesting new treatment avenues.
We report a synthetic tetrahedral DNA nanocarrier (TDN) for treating bone defects and methicillin-resistant Staphylococcus aureus (MRSA) infection using in vitro studies. We successfully synthesized TDNs and demonstrated their excellent cytocompatibility with blood cells and immune cells. Zoledronic acid-loaded TDN displayed increased efficacy compared to free drugs in regulating bone remodeling, while vancomycin-loaded TDN showed an increased antibacterial effect against MRSA. In the future, this nano-drug delivery platform, with its multifunctional properties, can be potentially used to treat bone fractures and surgery-related MRSA infection.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: